NanoEcho is a medical technology company that develops a diagnostic method for mapping the spread of rectal cancer to lymph nodes. The company's patented technology combines a magnetic field, iron oxide-based nanoparticles, and ultrasound to provide high-resolution imaging and improve treatment planning for healthcare providers.
Subscribe to see NanoEcho’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NanoEcho is a health care company headquartered in Sweden. Xcout tracks 6 named people at NanoEcho, including Fata Mrsic (CFO).
A few of NanoEcho's closest competitors — see the full list of competitors and alternatives →
iSono Health, Inc. specializes in automated breast imaging technology and provides diagnostic tools such as its FDA-cleared ATUSA system.
Smart Health Diagnostics Co. operates as a healthcare diagnostics holding company that oversees specialized portfolio businesses focused on pathology, oncology, and vascular diagnostics. The company provides slide-free digital pathology technology through its MUSE microscopy system and offers vascular diagnostic tools like SmartVascular Dx to detect vascular inflammation for clinicians and healthcare systems.
One Heart Health develops cost-effective medical technologies, including mobile screening tools and a proprietary app, to enable early diagnosis of congenital heart disease in children living in low-resource regions globally. The organization partners with local programs to facilitate screenings and connect affected children with life-saving cardiac surgeries.
Clarapath, Inc. is a U.S. medical-technology company developing robotic automation systems for anatomical pathology and histology workflows, including tissue processing and slide preparation. Its products are intended for hospital, clinical, and pathology laboratories to improve the efficiency and consistency of diagnostic specimen preparation.
CelLBxHealth plc is a medical diagnostics firm specializing in the creation of cancer detection solutions, with operations spanning the United Kingdom, broader Europe, North America, and other global markets. A flagship offering is the Parsortix PC1 system, a medical device engineered to isolate and collect whole circulating tumor cells (CTCs) from the blood of patients with metastatic breast cancer, preparing them for further user-validated analysis. The company also provides the Parsortix PR1 system for general CTC capture and collection from blood samples. Beyond its core systems, CelLBxHealth offers the Portrait+ CTC Staining kit, a laboratory solution designed for the precise identification, characterization, and quantification of both epithelial and mesenchymal circulating tumor cells, boasting strong analytical sensitivity and specificity. Another key product is the CellKeep Slide, which facilitates CTC harvesting. The company extends its expertise through various laboratory services, including advanced CTC enrichment and liquid biopsy analysis. Its assay portfolio comprises Portrait Flex, an immunofluorescence assay for detecting epithelial, mesenchymal, and epithelial-to-mesenchymal transition states, as well as assessing DNA damage response. Additionally, CelLBxHealth provides Portrait PD-L1 for CTC evaluation and develops customized CTC assays. Strategic collaborations underpin some of its development efforts; it has partnered with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. involves utilizing a pan-cancer next-generation sequencing (NGS) panel. Originally established in 1994 as ANGLE plc, the company rebranded to CelLBxHealth plc in October 2025 and operates from its base in Guildford, UK.
Check-Cap Ltd. is a medical diagnostics entity currently in its clinical development phase, dedicated to advancing screening solutions that utilize capsule-based technology. This firm was established in 2004 and conducts its primary operations from Isfiya, Israel.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.